Innovative sensor material enables non-invasive and early cancer diagnosis by analyzing metabolites in body fluids through light AI technology.
Vous n'êtes pas connecté
Highlights: cfDNA analysis can detect early-stage lung cancer with high accuracy through non-invasive blood tes
Innovative sensor material enables non-invasive and early cancer diagnosis by analyzing metabolites in body fluids through light AI technology.
A new case report was published in Oncoscience (Volume 11) on October 8, 2024, entitled, “Complete and long-lasting response to immunotherapy in...
A groundbreaking sensor material designed to diagnose cancer has been developed by a research team led by Dr. Ho Sang Jung at the Korea Institute of...
Speeding Up Cancer Detection: A newly developed, low-cost device detects cancer at lightning speed. Thus, early cancer diagnosis can increase the...
WEDNESDAY, Oct. 30, 2024 -- Cell-free DNA blood tests (cf-bDNA) may be more costly and less effective for colorectal cancer (CRC) screening than other...
UPM Biomedicals has launched FibGel, a natural injectable hydrogel for permanent implantable medical devices. FibGel is a nanofibrillar cellulose...
This is the story about Joe and the moment that changed my life.
The Cancer Control Agency is ignoring data showing the effectiveness of several drugs which are free to Australian patients, a leading specialist...
A new study from the MD Anderson Cancer Center reveals that quitting smoking within six months of a cancer diagnosis can significantly improve...
Evergreen Theragnostics, Inc., a clinical─stage radiopharmaceutical company, focused on providing additional treatment options for cancer patients,...